Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Positive Response to Registering Clinical Trials Seen (India)

This article was originally published in PharmAsia News

Executive Summary

India's medical research community has embraced the public registration of clinical trials, reports the latest issue of the British Medical Journal, and public registration today is the norm in India's clinical trial industry. Two years ago the International Committee of Medical Journal Editors (ICMJE) declared that only registered clinical trials would be considered as a reputable basis of published scientific articles. In response, registered worldwide clinical trials with the main U.S. database rose from 13,153 in 2005 to around 40,000 today. India-based researchers today have 467 clinical trials registered with the U.S. clinical trial registry. India's Council of Medical Research (ICMR) is working to create an India-specific national clinical trial registry. ICMR official Dr. Vasantha Muthuswamy says, "We are almost ready to launch the registry. It is undergoing a trial run." (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel